BPH (Benign Prostatic Hyperplasia)mPUL-ZANCT07776158
Efficacy and Safety of Modified Prostatic Urethral Lift (mPUL-ZA) for Benign Prostatic Hyperplasia
A study testing Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia in people with BPH (Benign Prostatic Hyperplasia), run by Qing Yuan at 1 site in China.
Trial summary
Abstract Background: Transurethral prostatic suspension and expansion, internationally referred to as prostatic urethral lift (PUL), is a minimally invasive treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Read more about this study
- Who is it for?
- Ages 50 to 80 years, men only
- Conditions the study is for
- BPH (Benign Prostatic Hyperplasia)
- What is being tested?
- Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2023to 27 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male patients aged 50 to 80 years old;
- Clinically diagnosed with benign prostatic hyperplasia accompanied by lower urinary tract symptoms;
- Prostate volume measured by transabdominal or transrectal ultrasonography ranges from 30 mL to 80 mL;
- International Prostate Symptom Score (IPSS) > 12 points;
- Maximum urinary flow rate (Qmax) ≤ 15 mL/s;
- Voided volume ≥ 125 mL during uroflowmetry examination;
Show all 13Show fewer
- Post-void residual urine volume (PVR) measured by ultrasonography < 350 mL;
- Having sexual intercourse within 6 months prior to enrollment;
- Sexual Health Inventory for Men (SHIM) score > 6 points;
- Preoperative clinical assessment confirms preservation of antegrade ejaculation;
- Judged by the investigator to be eligible for prostatic urethral lift;
- Able to understand the study content and voluntarily sign the written informed consent form;
- Able to complete all scheduled follow-up visits in accordance with the study protocol.
Who cannot join
- Urethral conditions that preclude insertion of a 20F cystoscopic scope;
- History of TURP, laser surgery, pelvic surgery, or radiotherapy;
- Total prostate-specific antigen (tPSA) > 10 ng/mL, or history of prostate cancer or bladder cancer;
- Neurogenic bladder, urethral stricture, severe coagulopathy, or concurrent use of anticoagulants contraindicated for the procedure;
- Intra-prostatic protrusion (IPP) > 1 cm;
- Other medical conditions or comorbidities contraindicating HoLEP or PUL;
- Refusal to disclose sexual function status.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy and Safety of Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia: A Prospective, Single-Center, Single-Arm Exploratory Study
Abstract
Background:
Read more
Transurethral prostatic suspension and expansion, internationally referred to as prostatic urethral lift (PUL), is a minimally invasive treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, implant deployment at the prostatic apex may be technically difficult because of limited lateral operating space and obstruction by the pubic arch. A modified technique involving zero-angle firing and needle-guided puncture was developed to facilitate implant placement in this region.
Objective:
This study aims to evaluate the feasibility, preliminary efficacy, and safety of the modified transurethral prostatic suspension and expansion procedure using zero-angle firing and needle-guided puncture in men with BPH-related lower urinary tract symptoms.
Methods:
This is a prospective, single-center, single-arm, open-label exploratory interventional study involving 12 male participants. The principal eligibility criteria include an age of 50-80 years, a prostate volume of 30-80 mL, an International Prostate Symptom Score (IPSS) greater than 12, a maximum urinary flow rate (Qmax) of 15 mL/s or less with a voided volume of at least 125 mL, and a post-void residual urine volume (PVR) of less than 350 mL. Patients with previous prostate surgery, confirmed or suspected prostate cancer, neurogenic bladder, urethral stricture, severe coagulation disorders, or anticoagulant therapy that cannot be safely discontinued or adjusted will be excluded.
All participants will undergo the modified transurethral prostatic suspension and expansion procedure. Implants will be deployed in the proximal and middle portions of the prostate using the conventional technique. At the prostatic apex, particularly when lateral rotation is restricted or pubic arch interference is anticipated, the delivery device will be maintained at the urethral midline in a neutral, zero-angle orientation. The needle will be fired in this position, followed by incremental manual compression to facilitate adequate tissue capture and needle-guided penetration of the prostatic capsule. The implant will then be tensioned and deployed.
Participants will be evaluated at baseline and followed at 14 days, 30 days, 90 days, and 12 months after surgery. The primary outcome is the change in IPSS from baseline to 90 days after surgery. Secondary outcomes include changes in quality-of-life score, Qmax, PVR, and Sexual Health Inventory for Men score; technical success; operative time; number of implants; estimated blood loss; catheterization duration; and length of hospital stay. Safety outcomes include gross hematuria, urinary urgency, dysuria, urinary retention, re-catheterization, urinary tract infection, urethral stricture, readmission, device-related adverse events, secondary intervention, and reoperation.
Continuous outcomes will be summarized using appropriate descriptive statistics and compared between baseline and follow-up using a paired-samples t-test or Wilcoxon signed-rank test, depending on the distribution of paired differences. Categorical variables will be reported as frequencies and percentages. All statistical tests will be two-sided, with a significance level of 0.05. Given the exploratory nature and small sample size, effect estimates and confidence intervals will be emphasized alongside P values.
Expected significance:
This study is expected to provide preliminary evidence regarding whether zero-angle firing and needle-guided puncture can facilitate implant deployment at the prostatic apex while improving urinary symptoms, urinary flow, and quality of life without adversely affecting erectile function. The findings may support the design of subsequent multicenter, controlled studies with larger sample sizes.
Keywords:
benign prostatic hyperplasia; lower urinary tract symptoms; transurethral prostatic suspension and expansion; prostatic urethral lift; zero-angle firing; needle-guided puncture; minimally invasive treatment
Registration information:
Study period: June 1, 2023 to December 31, 2023; ethics approval date: August 31, 2023; ethics approval number: S2023-493-01; principal investigator: Qing Yuan; planned sample size: 20 participants; registration status: retrospectively registered.
Read the detailed description
Abstract
Background:
Transurethral prostatic suspension and expansion, internationally referred to as prostatic urethral lift (PUL), is a minimally invasive treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, implant deployment at the prostatic apex may be technically difficult because of limited lateral operating space and obstruction by the pubic arch. A modified technique involving zero-angle firing and needle-guided puncture was developed to facilitate implant placement in this region.
Objective:
This study aims to evaluate the feasibility, preliminary efficacy, and safety of the modified transurethral prostatic suspension and expansion procedure using zero-angle firing and needle-guided puncture in men with BPH-related lower urinary tract symptoms.
Methods:
This is a prospective, single-center, single-arm, open-label exploratory interventional study involving 12 male participants. The principal eligibility criteria include an age of 50-80 years, a prostate volume of 30-80 mL, an International Prostate Symptom Score (IPSS) greater than 12, a maximum urinary flow rate (Qmax) of 15 mL/s or less with a voided volume of at least 125 mL, and a post-void residual urine volume (PVR) of less than 350 mL. Patients with previous prostate surgery, confirmed or suspected prostate cancer, neurogenic bladder, urethral stricture, severe coagulation disorders, or anticoagulant therapy that cannot be safely discontinued or adjusted will be excluded.
All participants will undergo the modified transurethral prostatic suspension and expansion procedure. Implants will be deployed in the proximal and middle portions of the prostate using the conventional technique. At the prostatic apex, particularly when lateral rotation is restricted or pubic arch interference is anticipated, the delivery device will be maintained at the urethral midline in a neutral, zero-angle orientation. The needle will be fired in this position, followed by incremental manual compression to facilitate adequate tissue capture and needle-guided penetration of the prostatic capsule. The implant will then be tensioned and deployed.
Participants will be evaluated at baseline and followed at 14 days, 30 days, 90 days, and 12 months after surgery. The primary outcome is the change in IPSS from baseline to 90 days after surgery. Secondary outcomes include changes in quality-of-life score, Qmax, PVR, and Sexual Health Inventory for Men score; technical success; operative time; number of implants; estimated blood loss; catheterization duration; and length of hospital stay. Safety outcomes include gross hematuria, urinary urgency, dysuria, urinary retention, re-catheterization, urinary tract infection, urethral stricture, readmission, device-related adverse events, secondary intervention, and reoperation.
Continuous outcomes will be summarized using appropriate descriptive statistics and compared between baseline and follow-up using a paired-samples t-test or Wilcoxon signed-rank test, depending on the distribution of paired differences. Categorical variables will be reported as frequencies and percentages. All statistical tests will be two-sided, with a significance level of 0.05. Given the exploratory nature and small sample size, effect estimates and confidence intervals will be emphasized alongside P values.
Expected significance:
This study is expected to provide preliminary evidence regarding whether zero-angle firing and needle-guided puncture can facilitate implant deployment at the prostatic apex while improving urinary symptoms, urinary flow, and quality of life without adversely affecting erectile function. The findings may support the design of subsequent multicenter, controlled studies with larger sample sizes.
Keywords:
benign prostatic hyperplasia; lower urinary tract symptoms; transurethral prostatic suspension and expansion; prostatic urethral lift; zero-angle firing; needle-guided puncture; minimally invasive treatment
Registration information:
Study period: June 1, 2023 to December 31, 2023; ethics approval date: August 31, 2023; ethics approval number: S2023-493-01; principal investigator: Qing Yuan; planned sample size: 20 participants; registration status: retrospectively registered.
- Conditions
- BPH (Benign Prostatic Hyperplasia)
- Being tested
- Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia
- Keywords
- benign prostatic hyperplasia, lower urinary tract symptoms, prostatic urethral lift, zero-angle firing, needle-guided puncture, minimally invasive treatment
- Medical subject headings
- Prostatic Hyperplasia, Lower Urinary Tract Symptoms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic HyperplasiaProcedure or surgery
Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia
| Study group | Role | What they receive |
|---|---|---|
| Single Surgical Intervention | Experimental | All enrolled patients receive unified surgical intervention, with standardized follow-up to observe clinical efficacy and safety indicators. Receives: Procedure: Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia |
What is being measured
The primary outcome is the main question the study is designed to answer.
International Prostate Symptom Score (IPSS) change from baseline
The IPSS score ranges from 0 to 35 points; higher scores indicate more severe lower urinary tract symptoms.
Measured: Intraoperative period
Quality of life (QoL) score change from baseline
QoL score ranges from 0 to 6 points; higher scores indicate poorer quality of life
Measured: intraoperative period
Maximum urinary flow rate (Qmax) change from baseline
Unit: ml/s; the higher the value, the better the urination function
Measured: Intra-operative period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start1 Jun 2023
- Primary completion31 Dec 2023
- Study completion27 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BPH (Benign Prostatic Hyperplasia)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qing Yuan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Qing Yuan, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07776158
- Sponsor's protocol ID
- S2023-493-01
- Acronym
- mPUL-ZA
- Status last verified
- Jun 2026
- First submitted
- 8 Aug 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia: A Prospective, Single-Center, Single-Arm Exploratory Study
- ClinicalTrials.gov ID
- NCT07776158
- Acronym / sponsor ID
- mPUL-ZA / S2023-493-01
- Conditions
- BPH (Benign Prostatic Hyperplasia)
- Keywords
- benign prostatic hyperplasia, lower urinary tract symptoms, prostatic urethral lift, zero-angle firing, needle-guided puncture, minimally invasive treatment
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Qing YuanUniversity, hospital or other
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 27 Nov 2024 (actual)
- First posted
- 20 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Abstract
Background:
Transurethral prostatic suspension and expansion, internationally referred to as prostatic urethral lift (PUL), is a minimally invasive treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, implant deployment at the prostatic apex may be technically difficult because of limited lateral operating space and obstruction by the pubic arch. A modified technique involving zero-angle firing and needle-guided puncture was developed to facilitate implant placement in this region.
Objective:
This study aims to evaluate the feasibility, preliminary efficacy, and safety of the modified transurethral prostatic suspension and expansion procedure using zero-angle firing and needle-guided puncture in men with BPH-related lower urinary tract symptoms.
Methods:
This is a prospective, single-center, single-arm, open-label exploratory interventional study involving 12 male participants. The principal eligibility criteria include an age of 50-80 years, a prostate volume of 30-80 mL, an International Prostate Symptom Score (IPSS) greater than 12, a maximum urinary flow rate (Qmax) of 15 mL/s or less with a voided volume of at least 125 mL, and a post-void residual urine volume (PVR) of less than 350 mL. Patients with previous prostate surgery, confirmed or suspected prostate cancer, neurogenic bladder, urethral stricture, severe coagulation disorders, or anticoagulant therapy that cannot be safely discontinued or adjusted will be excluded.
All participants will undergo the modified transurethral prostatic suspension and expansion procedure. Implants will be deployed in the proximal and middle portions of the prostate using the conventional technique. At the prostatic apex, particularly when lateral rotation is restricted or pubic arch interference is anticipated, the delivery device will be maintained at the urethral midline in a neutral, zero-angle orientation. The needle will be fired in this position, followed by incremental manual compression to facilitate adequate tissue capture and needle-guided penetration of the prostatic capsule. The implant will then be tensioned and deployed.
Participants will be evaluated at baseline and followed at 14 days, 30 days, 90 days, and 12 months after surgery. The primary outcome is the change in IPSS from baseline to 90 days after surgery. Secondary outcomes include changes in quality-of-life score, Qmax, PVR, and Sexual Health Inventory for Men score; technical success; operative time; number of implants; estimated blood loss; catheterization duration; and length of hospital stay. Safety outcomes include gross hematuria, urinary urgency, dysuria, urinary retention, re-catheterization, urinary tract infection, urethral stricture, readmission, device-related adverse events, secondary intervention, and reoperation.
Continuous outcomes will be summarized using appropriate descriptive statistics and compared between baseline and follow-up using a paired-samples t-test or Wilcoxon signed-rank test, depending on the distribution of paired differences. Categorical variables will be reported as frequencies and percentages. All statistical tests will be two-sided, with a significance level of 0.05. Given the exploratory nature and small sample size, effect estimates and confidence intervals will be emphasized alongside P values.
Expected significance:
This study is expected to provide preliminary evidence regarding whether zero-angle firing and needle-guided puncture can facilitate implant deployment at the prostatic apex while improving urinary symptoms, urinary flow, and quality of life without adversely affecting erectile function. The findings may support the design of subsequent multicenter, controlled studies with larger sample sizes.
Keywords:
benign prostatic hyperplasia; lower urinary tract symptoms; transurethral prostatic suspension and expansion; prostatic urethral lift; zero-angle firing; needle-guided puncture; minimally invasive treatment
Registration information:
Study period: June 1, 2023 to December 31, 2023; ethics approval date: August 31, 2023; ethics approval number: S2023-493-01; principal investigator: Qing Yuan; planned sample size: 20 participants; registration status: retrospectively registered.
Detailed description
Abstract
Background:
Transurethral prostatic suspension and expansion, internationally referred to as prostatic urethral lift (PUL), is a minimally invasive treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, implant deployment at the prostatic apex may be technically difficult because of limited lateral operating space and obstruction by the pubic arch. A modified technique involving zero-angle firing and needle-guided puncture was developed to facilitate implant placement in this region.
Objective:
This study aims to evaluate the feasibility, preliminary efficacy, and safety of the modified transurethral prostatic suspension and expansion procedure using zero-angle firing and needle-guided puncture in men with BPH-related lower urinary tract symptoms.
Methods:
This is a prospective, single-center, single-arm, open-label exploratory interventional study involving 12 male participants. The principal eligibility criteria include an age of 50-80 years, a prostate volume of 30-80 mL, an International Prostate Symptom Score (IPSS) greater than 12, a maximum urinary flow rate (Qmax) of 15 mL/s or less with a voided volume of at least 125 mL, and a post-void residual urine volume (PVR) of less than 350 mL. Patients with previous prostate surgery, confirmed or suspected prostate cancer, neurogenic bladder, urethral stricture, severe coagulation disorders, or anticoagulant therapy that cannot be safely discontinued or adjusted will be excluded.
All participants will undergo the modified transurethral prostatic suspension and expansion procedure. Implants will be deployed in the proximal and middle portions of the prostate using the conventional technique. At the prostatic apex, particularly when lateral rotation is restricted or pubic arch interference is anticipated, the delivery device will be maintained at the urethral midline in a neutral, zero-angle orientation. The needle will be fired in this position, followed by incremental manual compression to facilitate adequate tissue capture and needle-guided penetration of the prostatic capsule. The implant will then be tensioned and deployed.
Participants will be evaluated at baseline and followed at 14 days, 30 days, 90 days, and 12 months after surgery. The primary outcome is the change in IPSS from baseline to 90 days after surgery. Secondary outcomes include changes in quality-of-life score, Qmax, PVR, and Sexual Health Inventory for Men score; technical success; operative time; number of implants; estimated blood loss; catheterization duration; and length of hospital stay. Safety outcomes include gross hematuria, urinary urgency, dysuria, urinary retention, re-catheterization, urinary tract infection, urethral stricture, readmission, device-related adverse events, secondary intervention, and reoperation.
Continuous outcomes will be summarized using appropriate descriptive statistics and compared between baseline and follow-up using a paired-samples t-test or Wilcoxon signed-rank test, depending on the distribution of paired differences. Categorical variables will be reported as frequencies and percentages. All statistical tests will be two-sided, with a significance level of 0.05. Given the exploratory nature and small sample size, effect estimates and confidence intervals will be emphasized alongside P values.
Expected significance:
This study is expected to provide preliminary evidence regarding whether zero-angle firing and needle-guided puncture can facilitate implant deployment at the prostatic apex while improving urinary symptoms, urinary flow, and quality of life without adversely affecting erectile function. The findings may support the design of subsequent multicenter, controlled studies with larger sample sizes.
Keywords:
benign prostatic hyperplasia; lower urinary tract symptoms; transurethral prostatic suspension and expansion; prostatic urethral lift; zero-angle firing; needle-guided puncture; minimally invasive treatment
Registration information:
Study period: June 1, 2023 to December 31, 2023; ethics approval date: August 31, 2023; ethics approval number: S2023-493-01; principal investigator: Qing Yuan; planned sample size: 20 participants; registration status: retrospectively registered.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Surgical Intervention | Experimental | Procedure: Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic HyperplasiaAll enrolled patients receive unified surgical intervention, with standardized follow-up to observe clinical efficacy and safety indicators. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Male patients aged 50 to 80 years old;
- Clinically diagnosed with benign prostatic hyperplasia accompanied by lower urinary tract symptoms;
- Prostate volume measured by transabdominal or transrectal ultrasonography ranges from 30 mL to 80 mL;
- International Prostate Symptom Score (IPSS) > 12 points;
- Maximum urinary flow rate (Qmax) ≤ 15 mL/s;
Key exclusion criteria (7 listed)
- Urethral conditions that preclude insertion of a 20F cystoscopic scope;
- History of TURP, laser surgery, pelvic surgery, or radiotherapy;
- Total prostate-specific antigen (tPSA) > 10 ng/mL, or history of prostate cancer or bladder cancer;
- Neurogenic bladder, urethral stricture, severe coagulopathy, or concurrent use of anticoagulants contraindicated for the procedure;
- Intra-prostatic protrusion (IPP) > 1 cm;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic HyperplasiaModified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia | Procedure or surgery | Single Surgical Intervention |
Primary outcome
International Prostate Symptom Score (IPSS) change from baseline
Time frame: Intraoperative period
The IPSS score ranges from 0 to 35 points; higher scores indicate more severe lower urinary tract symptoms.
Quality of life (QoL) score change from baseline
Time frame: intraoperative period
QoL score ranges from 0 to 6 points; higher scores indicate poorer quality of life
Maximum urinary flow rate (Qmax) change from baseline
Time frame: Intra-operative period
Unit: ml/s; the higher the value, the better the urination function
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for BPH (Benign Prostatic Hyperplasia)
Recruiting
Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging
Benign Prostatic Hyperplasia (BPH)
Active, not recruitingPhase 4
Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction
BPH (Benign Prostatic Hyperplasia)
RecruitingObservational study
ProVIDE Studies Post Exit Analysis
BPH With Symptomatic Lower Urinary Tract Symptoms
Recruiting
Learning Curve of Tri-lobar HoLEP Versus En-bloc HoLEP
Benign Prostatic Hyperplasia With Outflow Obstruction
RecruitingObservational study
Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP
Prostatic Hyperplasia, Benign
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Modified Prostatic Urethral Lift Using a Zero-Angle Firing and Needle-Guided Puncture Technique for Benign Prostatic Hyperplasia in people with BPH (Benign Prostatic Hyperplasia), run by Qing Yuan at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
International Prostate Symptom Score (IPSS) change from baseline (time frame: Intraoperative period). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.